Alcohol withdrawal seizures

Epilepsy and Behavior

Volumn 15, Issue 2, 2009, Pages 92-97

  Hughes, John R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alcohol; Antiepileptic drugs; Benzodiazepines; Seizures; Withdrawal

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; CLORAZEPATE; DIAZEPAM; DISULFIRAM; DOPAMINE TRANSPORTER; FLUOXETINE; HALOPERIDOL; HOMOCYSTEINE; LORAZEPAM; MAGNESIUM SULFATE; MEPROBAMATE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALTREXONE DERIVATIVE; NEUROLEPTIC AGENT; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; PROTEIN SUBUNIT; SEROTONIN AGONIST; TIANEPTINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

ALCOHOL INTOXICATION; DISEASE COURSE; DRINKING BEHAVIOR; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; EXCITOTOXICITY; GENETIC ASSOCIATION; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; QT INTERVAL; REVIEW; RISK FACTOR; SIDE EFFECT; TONIC SEIZURE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; WITHDRAWAL SEIZURE; WITHDRAWAL SYNDROME;

ALCOHOL WITHDRAWAL SEIZURES; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RATS; RECEPTORS, GABA; RECEPTORS, N-METHYL-D-ASPARTATE; RISK FACTORS;

EID: 67349132377     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.02.037     Document Type: Review

References (71)

1. Snell L.D., Nunley K.R., Lickteig R.L., et al. Regional and subunit specific changes in NMDA receptor mRNA and immunoreactivity in mouse brain following ethanol ingestion. Brain Res Mol Brain Res 40 (1996) 71-78
2. Kalluri H.S., Mehta A.K., and Ticku M.R. Up-regulation of NMDA receptor subunit in rat brain following chronic ethanol treatment. Brain Res Mol Brain Res 508 (1998) 221-224
3. Ripley T.L., Dunworth S.J., and Stephens D.N. Effect of CGP39551 administration on the kindling of ethanol-withdrawal seizures. Psychopharmacology (Berl) 163 (2002) 157-165
4. Feng H.J., Yang L., and Faingold C.L. Role of the amygdala in ethanol withdrawal seizures. Brain Res 1141 (2007) 65-73
5. Liang J., Cagetti E., Olsen R.W., and Spigelman I. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. J Pharmacol Exp Ther 310 (2004) 1234-1245
6. Gorin-Meyer R.E., Wiren K.M., Tanchuck M.A., Long S.L., Yoneyama N., and Finn D.A. Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6J and DBA/2J mice. Neuroscience 146 (2007) 1302-1315
7. Veatch L.M., Wright T.M., and Randall C.L. Only male mice show sensitization of handling-induced convulsions across repeated ethanol withdrawal cycles. Alcohol Clin Exp Res 31 (2007) 477-4785
8. Uzbay I.T. Serotonergic anti-depressants and ethanol withdrawal syndrome: a review. Alcohol Alcohol 43 (2008) 15-24
9. Becker H.C., Myrick H., and Veatch L.M. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol 41 (2006) 399-406
10. Veatch L.M., and Becker H.C. Lorazepam and MK-801 effects on behavioral and electrographic indices of alcohol withdrawal sensitization. Brain Res 1065 (2005) 92-106
11. Rogawski M.A. Update on the neurobiology of alcohol withdrawal seizures. Epilepsy Curr 5 (2005) 225-230
12. Bleich S., Loffelholz K., and Kornhuber J. Folate against hyperhomocysteinemia: a new approach for the prevention and therapy of alcoholism-associated disorders?. Nervenarzt 75 (2004) 425-430
13. Hendricson A.W., Maldve R.E., Salinas A.G., et al. Aberrant synaptic activation of N-methyl-d-aspartate receptors underlies ethanol withdrawal hyperexitability. J Pharmacol Exp Ther 321 (2007) 60-72
14. Rujescu D., Soyka M., Dahmen N., et al. GRIN1 locus may modify the susceptibility to seizures during alcohol withdrawal. Am J Med Genet B Neuropsychiatr Genet 122B (2005) 85-87
15. Tadic A., Dahmen N., Szegedi A., et al. Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal-induced seizures and delirium tremens. Eur Arch Psychiatry Clin Neurosci 255 (2005) 129-135
16. Bleich S., Degner D., Sperling W., Bonsch D., Thurauf N., and Kornhuber J. Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 453-464
17. Soyka M., Preuss U.W., Hesselbrock V., Zill P., Koller G., and Bondy B. GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatr Res 42 (2008) 184-191
18. Fehr C., Sander T., Tadic A., et al. Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr Genet 16 (2006) 9-17
19. Kohnke M., Schick S., Lutz U., et al. The polymorphism GABABR1 T1974C[rs29230] of the GABAB receptor gene is not associated with the diagnosis of alcoholism or alcohol withdrawal seizures. Addict Biol 11 (2006) 152-156
20. Bleich S., Carl M., Bayerlein K., et al. Evidence of increased homocysteine levels in alcoholism: the Franconian Alcoholism Research Studies (FARS). Alcohol Clin Exp Res 29 (2005) 334-336
21. Lutz U.C., Batra A., Kolb W., Machicao F., Maurer S., and Kohnke M.D. Methylenetetrahydrofolate reductase C677T-polymorphism and its association with alcohol withdrawal seizure. Alcohol Clin Exp Res 30 (2006) 1966-1971
22. Bayerlein K., Hillemacher T., Reulbach U., et al. Alcoholism-associated hyperhomocysteinemia and previous withdrawal seizures. Biol Psychiatry 57 (2005) 1590-1593
23. Bleich S., Bayerlein K., Reulbach U., et al. Homocysteine levels in patients classified according to Lesch's typology. Alcohol Alcohol 39 (2004) 493-498
24. Bleich S., Bayerlein K., Hillemacher T., Degner D., Kornhuber J., and Frieling H. An assessment of the potential value of elevated homocysteine in predicting alcohol-withdrawal seizures. Epilepsia 47 (2006) 934-938
25. Hillemacher T., Frieling H., Bayerlein K., Wilhelm J., Kornhuber J., and Bleich S. Biological markers to predict previous alcohol withdrawal seizures: a risk assessment. J Neural Transm 114 (2007) 151-154
26. Bleich S., Sperling W., Degner D., et al. Lack of association between hippocampal volume reduction and first-onset alcohol withdrawal seizure: a volumetric MRI study. Alcohol Alcohol 38 (2003) 40-44
27. Brathen G. Alcohol and epilepsy. Tidsskr Nor Laegeforen 123 (2003) 1536-1538
28. Couvreur G., Demougeot C., Maugras C., Marie C., Beley P., and Giroud M. 5-Hydroxyindolacetic acid and homovanillic acid are not involved in the cerebrospinal fluid after a seizure in patients with delirium tremens. Neurol Res 24 (2002) 599-600
29. Gorwood P., Limosin F., Batel P., Hamon M., Ades J., and Boni C. The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure. Biol Psychiatry 53 (2003) 85-92
30. Limosin F., Loze J.Y., Boni C., et al. The A9 allele of the dopamine transporter gene increases the risk of visual hallucinations during alcohol withdrawal in alcohol-dependent women. Neurosci Lett 362 (2004) 91-94
31. Kohnke M.D., Batra A., Kolb W., et al. Association of the dopamine transporter gene with alcoholism. Alcohol Alcohol 40 (2005) 339-342
32. ′ part of the dopamine transporter gene DAT1/SLC6A3 is associated with withdrawal seizures in patients with alcohol dependence. Alcohol Clin Exp Res 32 (2008) 27-35
33. Wilhelm J., von Ahsen N., Hillemacher T., et al. Apolipoprotein E gene polymorphism and previous alcohol withdrawal seizures. J Psychiatr Res 41 (2007) 871-875
34. Preuss U.W., Koller G., Zill P., Bondy B., and Soyka M. Alcoholism-related phenotypes and genetic variants of the CB1 receptor. Eur Arch Psychiatry Clin Neurosci 253 (2003) 275-280
35. Preuss U.W., Koller G., Bahlmann M., Zill P., Soyka M., and Bondy B. No association between metabotropic glutamate receptors 7 and 8 (mGlur and mGlur8) gene polymorphisms and withdrawal seizures and delirium tremens in alcohol-dependent individuals. Alcohol Alcohol 37 (2002) 174-178
36. Preuss U.W., Zill P., Koller G., Bondy V., Hesselbrock V., and Soyka M. Ionotropic glutamate receptor gene GRIK3 SER310ALA functional polymorphism is related to delirium tremens in alcoholics. Pharmacogenomics J 6 (2006) 34-41
37. Cuculi F., Kobza R., Ehmann T., and Erne P. ECG changes amongst patients with alcohol withdrawal seizures and delirium tremens. Swiss Med Wkly 136 (2006) 223-227
38. Coutin-Churchman P., Moreno R., Anez Y., and Vergara F. Clinical correlates of quantitative EEG alterations in alcoholic patients. Clin Neurophysiol 117 (2006) 740-751
39. Fitzpatrick W., and Lowry N. PLEDs: clinical correlates. Can J Neurol Sci 34 (2007) 443-450
40. Chen W.H., Yin H.L., Lin H.S., Chen S.S., and Liu J.S. Delayed hypokalemic paralysis following a convulsion due to alcohol abstinence. J Clin Neurosci 13 (2006) 453-456
41. Rathlev N.K., Ulrich A., Shieh T.C., Callum M.G., Bernstein E., and D'Onofrio G. Etiology and weekly occurrence of alcohol-related seizures. Acad Emerg Med 9 (2002) 824-828
42. Hillbom M., Pieninkeroinen I., and Leone M. Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management. CNS Drugs 17 (2003) 1013-1030
43. Soyka M., Schmidt P., Franz M., et al. Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci 256 (2006) 395-401
44. Becker H.C. Kindling in alcohol withdrawal. Alcohol Health Res World 22 (1998) 25-33
45. Sim M.G., Hulse G., and Khong E. Alcohol and other drug uses in later life. Aust Fam Physician 33 (2004) 820-824
46. Christoffersen S. Death from seizures induced by chronic alcohol abuse: does it exist?. Seizure 16 (2007) 379-383
47. Alcohol withdrawal syndrome: how to predict, prevent, diagnose and treat it. Prescrire Int 2007;16:24-31.
48. Ritvo J.I., and Park C. The psychiatric management of patients with alcohol dependence. Curr Treat Options Neurol 9 (2007) 381-392
49. Mariani J.J., and Levin F.R. Pharmacotherapy for alcohol-related disorders: what clinicians should know. Harv Rev Psychiatry 12 (2004) 351-366
50. Riss J., Cloyd J., Gates J., and Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 118 (2008) 69-86
51. Kahan M., Borgundvaag B., Borsoi D., Edwards C., and Ladhani N. Treatment variability and outcome differences in the emergency department management of alcohol withdrawal. Can J Emerg Med 7 (2005) 87-92
52. Brathen G., Ben-Menachem E., Brodtkorb E., et al. For the EFNS task force on diagnosis and treatment of alcohol-related seizures. EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. Eur J Neurol 12 (2005) 575-581
53. Deutsch J.A., and Walton N.Y. Diazepam maintenance of alcohol preference during alcohol withdrawal. Science 198 (1977) 307-309
54. Ruskovic A., Horvat O., Jakovljevic V., et al. Interaction of alcoholic extracts of hops with pentobarbital and diazepam in mice. Eur J Drug Metab Pharmacokinet 32 (2007) 81-85
55. Takiguchi A., Masuoka T., Yamamoto Y., et al. Potentiation of ethanol in spatial memory deficits induced by some benzodiazepines. J Pharmacol Sci 101 (2006) 325-328
56. Lum E., Gorman S.K., and Slavik R.S. Valproic acid management of acute alcohol withdrawal. Ann Pharmacother 40 (2006) 441-448
57. Polycarpou A., Papanikolaou P., Ioannidis J.P., and Contopoulos-Ioannidis D.G. Anticonvulsants for alcohol withdrawal. Cochrane Dababase Syst Rev 3 (2005) CD005064
58. Ntais C., Pakos E., Kyzas P., and Ioannidis J.P. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 3 (2005) CD005063
59. Ponce G., Rodriguez-Jimenez R., Ortiz H., Rubio G., Jimenez-Arriero M.A., and Palomo T. Oxcarbazepine in the prevention of epileptic syndromes in alcohol detoxification. Rev Neurol 40 (2005) 577-580
60. Bayard M., McIntyre J., Hill K.R., and Woodside Jr. J. Alcohol withdrawal syndrome. Am Fam Physician 69 (2004) 1443-1450
61. Lucht M., Kuehn K.U., Armbruster J., et al. Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol 38 (2003) 168-175
62. Gartenmaier A., Pelzer E., and Soyka M. Treatment of alcohol withdrawal syndrome with combined carbamazepine and tiapride in a patient with probable sleep apnoea syndrome. Pharmacopsychiatry 38 (2005) 96-98
63. Rustembegovic A., Sofic E., Tahirovic I., and Kundurovic Z. A study of gabapentin in the treatment of tonic-clonic seizures of alcohol withdrawal syndrome. Med Arh 58 (2004) 5-6
64. Voris J., Smith N.L., Rao S.M., Thorne D.L., and Flowers Q.J. Gabapentin for the treatment of ethanol withdrawal. Subst Abus 24 (2003) 129-132
65. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 9 (2003) 559-568
66. Rustembegovic A., Sofic E., and Kroyer G. A pilot study of topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh 56 (2002) 211-212
67. Johnson B., Ait-Daoud N., Bowden C., et al. Oral topiramate for treatment of alcohol dependence. a randomized controlled trial. Lancet 361 (2003) 1677-1685
68. Book S.W., and Myrick H. Novel anticonvulsants in the treatment of alcoholism. Expert Opin Invest Drugs 14 (2005) 371-376
69. Johnson B.A., Rosenthal N., Capece A., et al. Oral topiramate for treatment of alcohol dependence. a randomized controlled trial. JAMA 298 (2007) 1641-1651
70. Garcia F.B., Pedraza C., and Navarro J.F. Update on gamma-hydroxybutyric acid. Rev Neurol 43 (2006) 39-48
71. Dissanaike S., Halldorsson A., Frezza E.E., and Griswold J. An ethanol protocol to prevent alcohol withdrawal syndrome. J Am Coll Surg 203 (2006) 186-191